Trial Outcomes & Findings for A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (NCT NCT05064059)

NCT ID: NCT05064059

Last Updated: 2025-09-17

Results Overview

OS was defined as the time from randomization to death due to any cause.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

441 participants

Primary outcome timeframe

Up to approximately 33 months

Results posted on

2025-09-17

Participant Flow

Participant milestones

Participant milestones
Measure	Standard of Care (Regorafenib or TAS-102) At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.	Favezelimab/Pembrolizumab Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
Overall Study STARTED	220	221
Overall Study Treated	210	221
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	220	221

Reasons for withdrawal

Reasons for withdrawal
Measure	Standard of Care (Regorafenib or TAS-102) At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.	Favezelimab/Pembrolizumab Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
Overall Study Death	196	199
Overall Study Physician Decision	2	4
Overall Study Sponsor Decision	11	14
Overall Study Withdrawal by Subject	11	4

Baseline Characteristics

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=220 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.	Total n=441 Participants Total of all reporting groups
Age, Continuous	59.9 Years STANDARD_DEVIATION 11.3 • n=93 Participants	57.6 Years STANDARD_DEVIATION 11.4 • n=4 Participants	58.8 Years STANDARD_DEVIATION 11.4 • n=27 Participants
Sex: Female, Male Female	83 Participants n=93 Participants	81 Participants n=4 Participants	164 Participants n=27 Participants
Sex: Female, Male Male	138 Participants n=93 Participants	139 Participants n=4 Participants	277 Participants n=27 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	19 Participants n=93 Participants	17 Participants n=4 Participants	36 Participants n=27 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	197 Participants n=93 Participants	196 Participants n=4 Participants	393 Participants n=27 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	5 Participants n=93 Participants	7 Participants n=4 Participants	12 Participants n=27 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants
Race (NIH/OMB) Asian	67 Participants n=93 Participants	65 Participants n=4 Participants	132 Participants n=27 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants
Race (NIH/OMB) Black or African American	5 Participants n=93 Participants	4 Participants n=4 Participants	9 Participants n=27 Participants
Race (NIH/OMB) White	145 Participants n=93 Participants	147 Participants n=4 Participants	292 Participants n=27 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	2 Participants n=4 Participants	2 Participants n=27 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants n=93 Participants	2 Participants n=4 Participants	6 Participants n=27 Participants
Geographic Region Asia Pacific	71 Participants n=93 Participants	70 Participants n=4 Participants	141 Participants n=27 Participants
Geographic Region EMEA/Americas	150 Participants n=93 Participants	150 Participants n=4 Participants	300 Participants n=27 Participants
Presence of Liver Metastasis Yes	172 Participants n=93 Participants	173 Participants n=4 Participants	345 Participants n=27 Participants
Presence of Liver Metastasis No	49 Participants n=93 Participants	47 Participants n=4 Participants	96 Participants n=27 Participants
Time from Initial Diagnosis of Metastatic Disease to Randomization ≥18 months	144 Participants n=93 Participants	150 Participants n=4 Participants	294 Participants n=27 Participants
Time from Initial Diagnosis of Metastatic Disease to Randomization <18 months	77 Participants n=93 Participants	70 Participants n=4 Participants	147 Participants n=27 Participants

PRIMARY outcome

Timeframe: Up to approximately 33 months

Population: All randomized participants were analyzed.

OS was defined as the time from randomization to death due to any cause.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=220 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Overall Survival (OS)	7.3 Months Interval 5.8 to 8.8	8.5 Months Interval 7.5 to 9.9

SECONDARY outcome

Timeframe: Up to approximately 21 months

Population: All randomized participants were analyzed.

PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=220 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	2.1 Months Interval 2.1 to 2.1	2.6 Months Interval 2.2 to 3.3

SECONDARY outcome

Timeframe: Up to approximately 21 months

Population: All randomized participants were analyzed.

ORR was defined as the percentage of participants who achieved a confirmed complete response (CR: Disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesion) per RECIST 1.1 as assessed by BICR.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=220 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR	6.8 Percentage of Participants Interval 3.8 to 10.9	0.9 Percentage of Participants Interval 0.1 to 3.2

SECONDARY outcome

Timeframe: Up to approximately 21 months

Population: All randomized participants who experienced a confirmed CR or PR were analyzed.

For participants who demonstrate confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions), duration of response was defined as the time from the first documented evidence of CR or PR until progressive disease (PD) or death due to any cause. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=15 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=2 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR	NA Months Interval 5.7 to NA = Median and upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.	NA Months NA = Median, lower limit, and upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.

SECONDARY outcome

Timeframe: Up to approximately 31 months

Population: All randomized participants who received at least one dose of study intervention were analyzed.

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=210 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Number of Participants Who Experienced at Least One Adverse Event (AE)	205 Participants	199 Participants

SECONDARY outcome

Timeframe: Up to approximately 28 months

Population: All randomized participants who received at least one dose of study intervention were analyzed.

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is presented.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=221 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=210 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Number of Participants Who Discontinued Study Treatment Due to an AE	21 Participants	19 Participants

SECONDARY outcome

Timeframe: Baseline and up to approximately 8 weeks

Population: All randomized participants who have received at least one dose of the study intervention and had at least one EORTC QLQ-C30 assessment data available for this outcome measure were analyzed.

The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=217 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=205 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score	-7.11 Score on a scale Interval -9.95 to -4.26	-4.03 Score on a scale Interval -7.05 to -1.0

SECONDARY outcome

Timeframe: Baseline and up to approximately 8 weeks

The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=217 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=205 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score	-7.13 Scores on a scale Interval -9.86 to -4.4	-6.17 Scores on a scale Interval -9.08 to -3.27

SECONDARY outcome

Timeframe: Baseline and up to approximately 8 weeks

The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, including a single-item scale score for appetite loss (QLQ-C30 Item 13). For this item, individual responses to the question "Have you lacked appetite?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 appetite loss (Item 13) scale score will be presented.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=217 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=205 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Change From Baseline in EORTC QLQ-C30 Appetite Loss (Item 13) Score	8.04 Score on a scale Interval 3.93 to 12.15	4.18 Score on a scale Interval -0.16 to 8.53

SECONDARY outcome

Timeframe: Baseline and up to approximately 8 weeks

Population: All randomized participants who have received at least one dose of the study intervention and had at least one EORTC QLQ-CR29 assessment data available for this outcome measure were analyzed.

The EORTC QLQ-CR29 is a health-related quality-of life (QoL) questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). For this item, individual responses to the question "Did you have a bloated feeling in your abdomen?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-CR29 bloating (Item 37) scale score will be presented.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=217 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=205 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Change From Baseline in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score	4.33 Score on a scale Interval 0.37 to 8.3	3.77 Score on a scale Interval -0.44 to 7.98

SECONDARY outcome

Timeframe: Baseline and up to approximately 38 months

Population: All randomized participants who have received at least one dose of the study intervention and had EORTC QLQ-C30 assessment data available at baseline for this outcome measure were analyzed.

TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in GHS (EORTC QLQ-C30 Item 29) \& QoL combined score (EORTC QLQ-C30 Item 30). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=210 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=193 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
Time to Deterioration (TTD) in EORTC QLQ-C30 GHS (Item 29) and QoL (Item 30) Combined Score	NA Months NA = Median, lower and upper limit were not reached due to insufficient number of participants with an event.	NA Months Interval 14.4 to NA = Median and upper limit were not reached due to insufficient number of participants with an event.

SECONDARY outcome

Timeframe: Baseline and up to approximately 38 months

TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=210 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=193 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score	NA Months Interval 9.1 to NA = Median and upper limit were not reached due to insufficient number of participants with an event.	20.3 Months Interval 10.9 to NA = Upper limit was not reached due to insufficient number of participants with an event.

SECONDARY outcome

Timeframe: Baseline and up to approximately 38 months

TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in appetite loss score (EORTC QLQ-C30 Item 13). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=210 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=193 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
TTD in in EORTC QLQ-C30 Appetite Loss (Item 13) Score	NA Months NA = Median, lower and upper limit were not reached due to insufficient number of participants with an event.	NA Months NA = Median, lower and upper limit were not reached due to insufficient number of participants with an event.

SECONDARY outcome

Timeframe: Baseline and up to approximately 38 months

Population: All randomized participants who have received at least one dose of the study intervention and had EORTC QLQ-CR29 assessment data available at baseline for this outcome measure were analyzed.

TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in bloating score (QLQ-CR29 Item 37). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in appetite loss score, will be presented. A longer TTD indicates a better outcome.

Outcome measures

Outcome measures
Measure	Favezelimab/Pembrolizumab n=208 Participants Participants received coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.	Standard of Care (Regorafenib or TAS-102) n=191 Participants At the Investigator's choice, participants received 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle OR 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score	NA Months Interval 17.4 to NA = Median and upper limit were not reached due to insufficient number of participants with an event.	NA Months NA = Median, lower and upper limit were not reached due to insufficient number of participants with an event.

Adverse Events

Favezelimab/Pembrolizumab

Serious events: 75 serious events

Other events: 193 other events

Deaths: 202 deaths

Standard of Care (Regorafenib or TAS-102)

Serious events: 56 serious events

Other events: 187 other events

Deaths: 203 deaths

Serious adverse events

Other adverse events

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme LLC

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
Publication restrictions are in place

Restriction type: OTHER